Research progress of uveitis associated with juvenile idiopathic arthritis

doi:10.3877/cma.j.issn.2095-2007.2023.01.008

Abstract

Abstract:

Juvenile idiopathic arthritis associated uveitis (JIA-U) is the most common extra-articular manifestation of juvenile idiopathic arthritis (JIA). JIA-U usually is characterized by chronic anterior uveitis, with insidious onset and often companying with vision-threatening complications. The goal of treatment for JIA-U is to reduce intraocular inflammation to zero or minimal activity to maintain immobility, which to be avoided various kinds of complications of JIA-U. It is of great benefit for ophthalmologists to understand the pathogenesis of JIA-U and associated risk factors, which to timely treat and reduce visual impairment with the greatest degree of effort. Therefore, the epidemic characteristics, pathogenesis, clinical manifestations, diagnosis and treatment of JIA-U were reviewed in this paper.

Key words: Juvenile idiopathic arthritis associated uveitis, Pathogenesis, Regular screening, Diagnosis, Treatment

Wenjie Li, Hong Lu. Research progress of uveitis associated with juvenile idiopathic arthritis[J]. Chinese Journal of Ophthalmologic Medicine(Electronic Edition), 2023, 13(01): 40-44.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhykyxzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-2007.2023.01.008

https://zhykyxzz.cma-cmc.com.cn/EN/Y2023/V13/I01/40

Figures/Tables 2

References 55

[1]	Petty RE, Southwood TR, Manners P, et al. International league of associations for rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001[J]. J Rheumatol, 2004, 31(2): 390－392.
[2]	Carlsson E, Beresford MW, Ramanan AV, et al. Juvenile idiopathic arthritis associated uveitis[J]. Children (Basel), 2021, 8(8): 646.
[3]	Sen ES, Ramanan AV. Juvenile idiopathic arthritis－associated uveitis[J]. Clin Immunol, 2020, 211: 108322.
[4]	Consolaro A, Giancane G, Alongi A, et al. Phenotypic variability and disparities in treatment and outcomes of childhood arthritis throughout the world: an observational cohort study[J]. Lancet Child Adolesc Health, 2019, 3(4): 255－263.
[5]	Clarke SLN, Mageean KS, Carlton H, et al. Environmental risk factors associated with juvenile idiopathic arthritis associated uveitis: a systematic review of the literature[J]. J Ophthalmic Inflamm Infect, 2021, PMID: 34027581.
[6]	Wei L, Zhou Q, Hou S, et al. MicroRNA－146a and Ets－1 gene polymorphisms are associated with pediatric uveitis[J]. PLoS One, 2014, 9(3): e91199.
[7]	Deng J, Tan H, Hu J, et al. Genetic aspects of idiopathic paediatric uveitis and juvenile idiopathic arthritis associated uveitis in Chinese Han[J]. Br J Ophthalmol, 2020, 104(3): 443－447.
[8]	Wennink RAW, de Boer JH, Hiddingh S, et al. Next－Generation HLA sequence analysis uncovers shared risk alleles between clinically distinct forms of childhood Uveitis[J]. Invest Ophthalmol Vis Sci, 2021, PMID: 34254975.
[9]	Walscheid K, Neekamp L, Heiligenhaus A, et al. Increased circulating proinflammatory T lymphocytes in children with different forms of anterior uveitis: results from a pilot study[J]. Ocul Immunol Inflamm, 2019, 27(5): 788－797.
[10]	Walscheid K, Neekamp L, Heiligenhaus A, et al. Peripheral blood monocytes reveal an activated phenotype in pediatric uveitis[J]. Clin Immunol, 2018, 190: 84－88.
[11]	Kalinina AV, van Dijk MR, de Boer JH. Infiltration of plasma cells in the iris of children with ana－positive anterior uveitis[J]. Invest Ophthalmol Vis Sci, 2015, 56(11): 6770－6778.
[12]	Wildschütz L, Ackermann D, Witten A, et al. Transcriptomic and proteomic analysis of iris tissue and aqueous humor in juvenile idiopathic arthritis－associated uveitis[J]. J Autoimmun, 2019, 100: 75－83.
[13]	Wennink RAW, Pandit A, Haasnoot AJW, et al. Whole transcriptome analysis reveals heterogeneity in B cell memory populations in patients with juvenile idiopathic arthritis－associated uveitis[J]. Front Immunol, 2020, PMID: 33042130.
[14]	Busch M, Wefelmeyer KL, Walscheid K, et al. Identification of ocular autoantigens associated with juvenile idiopathic arthritis－associated uveitis[J]. Front Immunol, 2019, PMID: 31447836.
[15]	Wang J, Wu H, Liu X, et al. Effect of LPS on cytokine secretion from peripheral blood monocytes in juvenile idiopathic arthritis－associated uveitis patients with positive antinuclear antibody[J]. J Immunol Res, 2021, PMID: 34056011.
[16]	Sijssens KM, Rijkers GT, Rothova A, et al. Cytokines, chemokines and soluble adhesion molecules in aqueous humor of children with uveitis[J]. Exp Eye Res, 2007, 85(4): 443－449.
[17]	Drozdova EA, Yadykina EV, Mezentseva EA, et al. Cytokine profile changes in children with juvenile idiopathic arthritis－associated uveitis[J]. Vestn Oftalmol, 2017, 133(1): 27－31.
[18]	Walscheid K, Heiligenhaus A, Holzinger D, et al. Elevated S100A8/A9 and S100A12 serum levels reflect intraocular inflammation in juvenile idiopathic arthritis－associated uveitis: results from a pilot study[J]. Invest Ophthalmol Vis Sci, 2015, 56(13): 7653－7660.
[19]	Haasnoot AM, Kuiper JJ, Hiddingh S, et al. Ocular fluid analysis in children reveals interleukin－29/interferon－λ1 as a biomarker for juvenile idiopathic arthritis－associated uveitis[J]. Arthritis Rheumatol, 2016, 68(7): 1769－1779.
[20]	Clarke SL, Sen ES, Ramanan AV. Juvenile idiopathic arthritis－associated uveitis[J]. Pediatr Rheumatol Online J, 2016, 14(1): 27.
[21]	Cosickic A, Halilbasic M, Selimovic A, et al. Uveitis associated with juvenile idiopathic arthritis, our observations[J]. Med Arch, 2017, 71(1): 52－55.
[22]	Chen JL, Abiri P, Tsui E. Recent advances in the treatment of juvenile idiopathic arthritis－associated uveitis[J]. Ther Adv Ophthalmol, 2021, PMID: 33681703.
[23]	American Academy of Pediatrics Section on Rheumatology and Section on Ophthalmology. Guidelines for ophthalmologic examinations in children with juvenile rheumatoid arthritis[J]. Pediatrics, 1993, 92(2): 295－296.
[24]	Angeles－Han ST, Ringold S, Beukelman T, et al. 2019 American college of rheumatology/arthritis foundation guideline for the screening, monitoring, and treatment of juvenile idiopathic arthritis－associated uveitis[J]. Arthritis Care Res, 2019, 71(6): 703－716.
[25]	Liebling EJ, Faig W, Chang JC, et al. Temporal relationship between juvenile idiopathic arthritis disease activity and uveitis disease activity[J]. Arthritis Care Res (Hoboken), 2022, 74(3): 349－354.
[26]	Cassidy J, Kivlin J, Lindsley C, et al. Ophthalmologic examinations in children with juvenile rheumatoid arthritis[J]. Pediatrics, 2006, 117(5): 1843－1845.
[27]	Thomas AS. Biologics for the treatment of noninfectious uveitis: current concepts and emerging therapeutics[J]. Curr Opin Ophthalmol, 2019, 30(3): 138－150.
[28]	Angeles－Han ST, McCracken C, Yeh S, et al. Characteristics of a cohort of children with juvenile idiopathic arthritis and JIA－associated uveitis[J]. Pediatr Rheumatol Online J, 2015, PMID: 26031738.
[29]	Constantin T, Foeldvari I, Anton J, et al. Consensus－based recommendations for the management of uveitis associated with juvenile idiopathic arthritis: the SHARE initiative[J]. Ann Rheum Dis, 2018, 77(8): 1107－1117.
[30]	侯蕾，刘礼初，邢基斯. 36例幼年特发性关节炎病例回顾性研究[J]. 世界中西医结合杂志，2015，10(4)：511－513，517.
[31]	Kostik MM, Gaidar EV, Hynnes AY, et al. Methotrexate treatment may prevent uveitis onset in patients with juvenile idiopathic arthritis: experiences and subgroup analysis in a cohort with frequent methotrexate use[J]. Clin Exp Rheumatol, 2016, 34(4): 714－718.
[32]	Simonini G, Paudyal P, Jones GT, et al. Current evidence of methotrexate efficacy in childhood chronic uveitis: a systematic review and meta－analysis approach[J]. Rheumatology (Oxford), 2013, 52(5): 825－831.
[33]	Wieringa WG, Armbrust W, Legger GE, et al. Efficacy of high－dose methotrexate in pediatric non－infectious uveitis[J]. Ocul Immunol Inflamm, 2019, 27(8): 1305－1313.
[34]	Tirelli F, Zannin ME, Vittadello F, et al. Methotrexate monotherapy in juvenile idiopathic arthritis associated uveitis: myth or reality？[J]. Ocul Immunol Inflamm, 2022, PMID: 34287104.
[35]	Simonini G, Bracaglia C, Cattalini M, et al. Predictors of relapse after discontinuing systemic treatment in childhood autoimmune chronic uveitis[J]. J Rheumatol, 2017, 44(6): 822－826.
[36]	Cheung CSY, Mireskandari K, Ali A, et al. Earlier use of systemic immunosuppression is associated with fewer ophthalmic surgeries in paediatric non－infectious uveitis[J]. Br J Ophthalmol, 2020, 104(7): 938－942.
[37]	Doycheva D, Deuter C, Stuebiger N, et al. Mycophenolate mofetil in the treatment of uveitis in children[J]. Br J Ophthalmol, 2007, 91(2): 180－184.
[38]	Goebel JC, Roesel M, Heinz C, et al. Azathioprine as a treatment option for uveitis in patients with juvenile idiopathic arthritis[J]. Br J Ophthalmol, 2011, 95(2): 209－213.
[39]	Kilmartin DJ, Forrester JV, Dick AD. Cyclosporin a therapy in refractory non－infectious childhood uveitis[J]. Br J Ophthalmol, 1998, 82(7): 737－742.
[40]	Quartier P, Baptiste A, Despert V, et al. ADJUVITE: a double－blind, randomised, placebo－controlled trial of adalimumab in early onset, chronic, juvenile idiopathic arthritis－associated anterior uveitis[J]. Ann Rheum Dis, 2018, 77(7): 1003－1011.
[41]	Ramanan AV, Dick AD, Jones AP, et al. Adalimumab in combination with methotrexate for refractory uveitis associated with juvenile idiopathic arthritis: a RCT[J]. Health Technol Assess, 2019, PMID: 31033434.
[42]	Leinonen ST, Aalto K, Kotaniemi KM, et al. Anti－adalimumab antibodies in juvenile idiopathic arthritis－related uveitis[J]. Clin Exp Rheumatol, 2017, 35(6): 1043－1046.
[43]	Tappeiner C, Mesquida M, Adán A, et al. Evidence for tocilizumab as a treatment option in refractory uveitis associated with juvenile idiopathic arthritis[J]. J Rheumatol, 2016, 43(12): 2183－2188.
[44]	Maleki A, Manhapra A, Asgari S, et al. Tocilizumab employment in the treatment of resistant juvenile idiopathic arthritis associated uveitis[J]. Ocul Immunol Inflamm, 2021, 29(1): 14－20.
[45]	Mesquida M, Molins B, Llorenç V, et al. Long－term effects of tocilizumab therapy for refractory uveitis－related macular edema[J]. Ophthalmology, 2014, 121(12): 2380－2386.
[46]	Ramanan AV, Dick AD, Guly C, et al. Tocilizumab in patients with anti－TNF refractory juvenile idiopathic arthritis－associated uveitis (APTITUDE): a multicentre, single－arm, phase 2 trial[J]. Lancet Rheumatol, 2020, 2(3): e135－e141.
[47]	Birolo C, Zannin ME, Arsenyeva S, et al. Comparable efficacy of abatacept used as first－line or second－line biological agent for severe juvenile idiopathic arthritis－related uveitis[J]. J Rheumatol, 2016, 43(11): 2068－2073.
[48]	Schwartz DM, Kanno Y, Villarino A, et al. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases[J]. Nat Rev Drug Discov, 2017, 16(12): 843－862.
[49]	Taylor PC. Clinical efficacy of launched JAK inhibitors in rheumatoid arthritis[J]. Rheumatology (Oxford), 2019, 58(S1): i17－i26.
[50]	Bing SJ, Lyu C, Xu B, et al. Tofacitinib inhibits the development of experimental autoimmune uveitis and reduces the proportions of Th1 but not of Th17 cells[J]. Mol Vis, 2020, 26: 641－651.
[51]	Bauermann P, Heiligenhaus A, Heinz C. Effect of janus kinase inhibitor treatment on anterior uveitis and associated macular edema in an adult patient with juvenile idiopathic arthritis[J]. Ocul Immunol Inflamm, 2019, 27(8): 1232－1234.
[52]	Miserocchi E, Giuffrè C, Cornalba M, et al. JAK inhibitors in refractory juvenile idiopathic arthritis－associated uveitis[J]. Clin Rheumatol, 2020, 39(3): 847－851.
[53]	Miserocchi E, Modorati G, Berchicci L, et al. Long－term treatment with rituximab in severe juvenile idiopathic arthritis－associated uveitis[J]. Br J Ophthalmol, 2016, 100(6): 782－786.
[54]	Gaffney KJ, Dahl EM, Stanton MP, et al. Rapid－infusion rituximab in a pediatric population[J]. J Pediatr Pharmacol Ther, 2020, 25(3): 215－219.
[55]	Maleki A, Anesi SD, Look－Why S, et al. Pediatric uveitis: A comprehensive review[J]. Surv Ophthalmol, 2022, 67(2): 510－529.

Please choose a citation manager

Content to export